AMWILL HEALTH CARE LIMITED has announced the signing of an Exclusive Manufacturing, Private Label Supply, Import & Non-Disclosure Agreement with a leading pharmaceutical manufacturing company based in Thailand. This agreement, effective from November 13, 2026, allows the Thai company to manufacture Hair Color products under AMWILL’s brand for import and sale in India. The deal is for a term of 5 years, renewable by mutual consent, aiming to broaden AMWILL’s product portfolio and enhance its market presence.
Strategic Manufacturing Agreement Signed
AMWILL HEALTH CARE LIMITED has entered into a significant agreement with a prominent pharmaceutical manufacturing company located in Thailand. This new partnership, formalized on November 13, 2026, establishes an Exclusive Manufacturing, Private Label Supply, Import & Non-Disclosure Agreement.
Key Terms of the Agreement
Under the terms of this accord, the Thai manufacturer will produce Hair Color products specifically for AMWILL, utilizing a private-label model. AMWILL will then import these finished goods for marketing and sale within India and other designated territories. The agreement has been set for an initial term of 5 years, with the provision for renewal based on mutual consent, ensuring a long-term strategic alignment.
Business Rationale and Expected Benefits
The primary objective behind this collaboration is to expand AMWILL’s existing product portfolio within the Hair Color segment. Furthermore, the agreement aims to strengthen and diversify the company’s sourcing capabilities for quality pharmaceutical products. This strategic move is anticipated to enable AMWILL to offer a broader range of products to its customer base, thereby supporting its overall business growth. The actual realization of benefits will be contingent upon factors such as regulatory approvals, prevailing market conditions, and commercial performance.
No Upfront Payment
It is noteworthy that there is no upfront payment involved in this agreement, indicating a risk-mitigated approach to this new venture.
Agreement Details
The agreement is exclusive, and the manufacturer is responsible for adhering to applicable Good Manufacturing Practices (GMP) and quality standards. AMWILL will be responsible for securing regulatory registrations, as well as all marketing and distribution activities within the specified territory. Other terms of the agreement are considered customary for arrangements of this nature.
Source: BSE
